Drugs & Targets FDA proposes rule aimed at ensuring safety and effectiveness of laboratory developed tests October 06, 2023Vol.49 No.37
Drugs & Targets FDA establishes pilot program to accelerate development of rare disease therapies October 06, 2023Vol.49 No.37
Capitol Hill Most NIH activities will cease immediately if government shuts down September 29, 2023Vol.49 No.36By Matthew Bin Han Ong
Drugs & Targets FDA clears automated assay to assess tumor progression in neuroendocrine cancer September 29, 2023Vol.49 No.36
Drugs & Targets Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression September 29, 2023Vol.49 No.36
Drugs & Targets FDA grants Merck sBLA priority review for Keytruda + chemoradiotherapy in cervical cancer September 22, 2023Vol.49 No.35
Funding Opportunities FDA opens application for Orphan Products Clinical Trials Grant Program September 15, 2023Vol.49 No.34
Drugs & Targets FDA grants accelerated approval to Elrexfio for r/r multiple myeloma September 08, 2023Vol.49 No.33
Drugs & Targets FDA places partial clinical hold for magrolimab studies in AML September 08, 2023Vol.49 No.33
